Research programme: hepatitis B therapeutics - Chromis TherapeuticsAlternative Names: CHR-101
Latest Information Update: 01 Mar 2016
At a glance
- Originator Chromis Therapeutics
- Class Small molecules
- Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors; Virus internalisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 25 Feb 2016 Preclinical development in Hepatitis B in USA (PO)